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Summary
Background Understanding genetic variations is important in predicting treatment
response and forms the basis for identifying new pharmacogenetic and pharma-
cogenomic targets for psoriasis treatment. There are limited data on the efficacy
of secukinumab in relation to genetic markers.
Objectives To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-
positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-
to-severe chronic plaque-type psoriasis.
Methods SUPREME was a 24-week, phase IIIb study with an extension period up
to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90
response rate after 16 weeks.
Results In total, 434 patients were recruited: 185 (426%) were Cw6-POS and
246 (567%) were Cw6-NEG (three not assessed). Mean  SD age was
452  132 years (Cw6-POS 427  131; Cw6-NEG 472  129). The base-
line PASI score was comparable between the cohorts [Cw6-POS 207  899;
Cw6-NEG 215  999 (P = 0777)]. At week 16, PASI 90 was achieved in
804% of Cw6-POS and 797% of Cw6-NEG patients (difference 076; 95% con-
fidence interval 704 to 823). No differences in absolute PASI at week 16
(Cw6-POS 136  358; Cw6-NEG 118  229) were observed. The overall
safety profile of secukinumab was consistent with that previously reported. No
statistically significant difference was detected in the rate of treatment-emergent
adverse events [Cw6-POS 427%; Cw6-NEG 496% (P = 0295)]. A high PASI 90
response was achieved with secukinumab with a fast reduction in absolute PASI.
Conclusions Determination of HLA-Cw6 status for secukinumab therapy is unneces-
sary, as it is highly effective regardless of HLA-Cw6 status.
What’s already known about this topic?
• HLA-Cw6 is associated with the phenotypic features of psoriasis and positive
response to ustekinumab and is present in approximately 40–80% of cases.
• Secukinumab is a fully human monoclonal antibody neutralizing interleukin-17A
and it has demonstrated a rapid onset of action and sustained responses with a
favourable safety profile in moderate-to-severe psoriasis, psoriatic arthritis and
ankylosing spondylitis.
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What does this study add?
• Although HLA-Cw6-positive and HLA-Cw6-negative patients have distinct clinical fea-
tures, the present study showed that secukinumab achieved similar clinical
responses in both cohorts after 24 weeks of treatment.
• There was no difference in efficacy regarding HLA-Cw6 status.
Chronic plaque-type psoriasis is the most common form of
plaque psoriasis and is characterized by increased proliferation
of keratinocytes, hyperplasia of the epidermis, strong inflam-
matory infiltrate of the dermis and marked dilation of vessels
in the papillary dermal region, leading to the formation of
well-demarcated, red, raised and scaly plaques.1–3 Pathogenesis
of plaque psoriasis involves a complex interaction of genetic,
environmental and immunological factors.1
The understanding of the genetic variations is pivotal in
predicting the treatment response and forms the basis for
identifying new pharmacogenetic and pharmacogenomic tar-
gets for the treatment of psoriasis.4,5 Genetic linkage and asso-
ciation studies have identified several chromosomal loci linked
to psoriasis susceptibility.6,7 A recent meta-analysis of psoriasis
genetic predisposition identified 52 different psoriasis suscep-
tibility (PSORS) loci associated with increased risk of develop-
ing the disease.8 Among these, PSORS1, located within the
major histocompatibility complex on chromosome 6p21, is
associated with the greatest risk for early-onset (type 1) psori-
asis. The most likely PSORS1 allele is HLA-Cw6, which is asso-
ciated with the phenotypic features of psoriasis and present in
approximately 40–80% of cases.1,7,9–12 HLA-Cw6 is associated
with more severe and early-onset psoriasis, and Caucasian
patients who are carriers of this allele have about a 10-fold
increased risk of developing psoriasis.13
Recent studies have shown that biological drugs approved
for treating psoriasis and psoriatic arthritis (PsA) are not effec-
tive in all patients, and that variations in the genome have
been associated with different clinical responses or side-
effects.14–18 For example, ustekinumab, a human monoclonal
antibody against interleukin (IL)-12 and IL-23, has shown a
superior and faster response in HLA-Cw6-positive (Cw6-POS)
patients than in HLA-Cw6-negative (Cw6-NEG) patients with
moderate-to-severe psoriasis.17,19 Secukinumab is a fully
human monoclonal antibody that neutralizes IL-17A and it has
demonstrated a rapid onset of action and sustained responses
with a favourable safety profile in moderate-to-severe psoria-
sis, PsA and ankylosing spondylitis.20–27 The efficacy of secuk-
inumab has been established in different indications; however,
little is known about the potential differences in response to
secukinumab treatment between patients stratified for the
presence of a genetic biomarker. SUPREME was a phase IIIb
study (ClinicalTrials.gov identifier NCT02394561) conducted
to explore the efficacy and safety profile of secukinumab
300 mg in patients with moderate-to-severe chronic
plaque-type psoriasis, stratified by HLA-Cw6 status. Herein, we
present the efficacy and safety results from the core study.
Materials and methods
Study design
The SUPREME core study was a 24-week, phase IIIb, multi-
centre, prospective study conducted across 50 centres in
Italy, with an extension period up to 72 weeks. The study
consisted of four periods: (i) a screening period consisting
of two visits (prescreening and screening); (ii) an induction
period of 4 weeks; (iii) a maintenance period of 20 weeks;
and (iv) an extension period of at least 12 weeks and up to
48 weeks. There were 12 study visits [weeks 4, 2, 0
(baseline), 1, 2, 3, 4, 8, 12, 16, 20 and 24]. Patients were
centrally assessed for HLA-Cw6 positivity or negativity at the
prescreening visit (week 4 and day 28) and stratified into
two cohorts. HLA-Cw6 status was blinded for both the
patients and the investigators. After the full screening visit
(week 2 and day 14 to 7), eligible patients were treated
with subcutaneous secukinumab 300 mg (two 150 mg injec-
tions) per week for the first 5 weeks (visits 3–7) starting at
baseline (week 0), followed by a maintenance period of
300 mg (two 150 mg injections) per month (visits 8–12).
Psoriasis severity was evaluated at week 16, and patients
achieving at least a Psoriasis Area and Severity Index (PASI)
50 response were eligible to continue the study treatment
for an additional 8 weeks up to 24 weeks. Patients achieving
PASI 75 at the end of 24 weeks were eligible to enter the
48-week extension phase.
Patients
Male or female patients aged ≥ 18 years diagnosed with mod-
erate-to-severe chronic plaque-type psoriasis of at least
6 months’ duration (including patients with concomitant nail,
scalp or PsA according to the Classification Criteria for Psori-
atic Arthritis) were included in the study. Moderate-to-severe
plaque-type psoriasis was defined at enrolment by: PASI score
≥ 10 or PASI score > 5 but < 10 and Dermatology Life Qual-
ity Index ≥ 10. As a consequence of the European Medicines
Agency’s approval of secukinumab in February 2015, inclu-
sion criteria were updated in order to guarantee treatment to
systemic na€ıve patients, as per label, other than to patients
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na€ıve to, intolerant to or failing a previous biological treat-
ment with anti-tumour necrosis factor (TNF)-a therapy.
Key exclusion criteria included forms of psoriasis other than
chronic plaque type (e.g. pustular, erythrodermic and guttate pso-
riasis), ciclosporin or methotrexate administration within 4 weeks
prior to day 1, and previous exposure to any biological drug for
the treatment of psoriasis that was not anti-TNF-a therapy
All patients provided written informed consent before
enrolment into the study. The study protocol was approved by
the institutional review board of each participating centre. The
trial was conducted in accordance with the Declaration of Hel-
sinki and Good Clinical Practice, and in compliance with all
federal, local and regional requirements.
Study end points
The primary end point was a PASI 90 response rate in Cw6-NEG
and Cw6-POS patients after 16 weeks. The key secondary end
points were comparison of the following parameters between the
cohorts: proportion of responders to PASI 50, PASI 75, PASI 90
and PASI 100 over time; mean changes from baseline in the Inves-
tigator’s Global Assessment modified in 2011 (IGA mod 2011)
over time; time to reach PASI 90 and PASI 75; and safety and toler-
ability for 24 weeks and for up to 72 weeks thereafter.
Assessments
Efficacy
The severity of psoriasis was measured using PASI, at each
visit from visit 2 to visit 12. PASI combines the assessment of
the severity of lesions and the area affected into a single score
with a range of 0 (no disease) to 72 (maximal disease).28
PASI 50, PASI 75 and PASI 90 were defined as the achieve-
ment of ≥ 50%, ≥ 75% and ≥ 90% improvement (reduction)
in PASI score vs. baseline, respectively. PASI 100 was defined
as the achievement of complete clearing of psoriasis
(PASI = 0). The IGA mod 2011 scale was used to assess over-
all psoriatic disease on a 5-point scale ranging from 0 (no dis-
ease, ‘clear’) to 4 (‘very severe’).29
Safety
Haematology and clinical chemistry assessments were per-
formed at visits 2 and 3 and then at each visit starting from
visit 7. Urinalysis was performed at visits 2, 10 and 12. Elec-
trocardiogram and chest X-ray were performed at visit 2
(baseline). All reported adverse events (AEs) were coded using
the Medical Dictionary for Regulatory Activities terminology
and were recorded by severity (mild, moderate or severe),
relationship to the study drug, duration and outcome.
DNA extraction and genotyping
HLA-Cw6 status was determined as previously described.17,18
Briefly, venous blood for genotyping was collected in
ethylenediaminetetraacetic acid (EDTA) tubes and stored at
70 °C. DNA was extracted from whole blood using
DNAeasy blood and tissue kit (Qiagen, Hilden, Germany).
HLA-Cw6 allele was detected by standard polymerase chain
reaction using allele-specific primers (forward 50 TACTA-
CAACC AGAGCGAGGA-30; reverse 50-GGTCGCAGCCATA-
CATCCA-30).
Statistical analysis
The primary end point was the proportion of PASI 90 after
16 weeks of treatment. Assuming an enrolment rate of 60%
for Cw6-POS patients, a one-sided alpha level of 0025 and a
power of 80%, 365 patients (219 Cw6-POS and 146 Cw6-
NEG) were deemed sufficient to evaluate if the response in
terms of PASI 90 in the Cw6-NEG cohort was not < 12%
compared with the Cw6-POS cohort. The full analysis set
includes all the enrolled patients (n = 434). The safety set
includes all enrolled patients who were given at least one dose
of the study drug (n = 434). The intent-to-treat (ITT) set
includes all patients in the safety population with at least one
postbaseline efficacy assessment and Cw6 assessment
(n = 430). The primary and secondary objectives were evalu-
ated on the ITT population, and all safety evaluations were
performed on the safety population. The proportion of
patients who achieved PASI 90 at 16 weeks was presented
with a one-tailed 975% confidence interval (CI) of the differ-
ence between Cw6-POS and Cw6-NEG. For patients who pre-
maturely discontinued the study for any reason or patients
with missing visits (after baseline), PASI was imputed using
the last observation carried forward (LOCF) approach.
Nonresponder imputation analysis was also performed. If all
PASI postbaseline efficacy values were missing, then these
missing values were not imputed, and this patient was
removed from the analysis. A regression analysis was per-
formed taking into account the patients’ baseline characteris-
tics, in order to balance the two cohorts. Differences in
baseline characteristics between cohorts were explored. A Cox
proportional hazard regression model was used to analyse
time taken to achieve PASI 90/PASI 75.
All statistical analyses were performed using SAS software
9.2 (SAS Institute, Cary, NC, U.S.A.).
Results
Patient demographics and disease characteristics
In total, 533 patients were screened and 434 were enrolled in
the study (Fig. 1). Of these, 185 (426%) patients were Cw6-
POS and 246 (567%) were Cw6-NEG; HLA-Cw6 was not
assessed for three patients. Overall, 402 (926%) patients com-
pleted the core phase (24 weeks), in particular 172 (930%)
Cw6-POS and 227 (923%) Cw6-NEG patients. The main rea-
sons for discontinuation were AEs (overall 37%; Cw6-POS
38%; Cw6-NEG 37%) and lack of efficacy (overall 16%;
Cw6-POS 05%; Cw6-NEG 24%).
© 2018 The Authors. British Journal of Dermatology
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Baseline demographics and disease characteristics, by overall
study population and cohorts, are shown in Table 1. The
mean  SD age of the overall study population was
452  132 years; Cw6-POS patients were significantly younger
than Cw6-NEG patients (427  131 vs. 472  129;
P < 0001). No significant difference was observed with regard
Fig 1. Patient disposition. Cw6-NEG, HLA-Cw6 negative; Cw6-POS, HLA-Cw6-positive.
Table 1 Baseline demographics and disease characteristics
Cw6-POS (n = 185) Cw6-NEG (n = 246) P-valuea Overall (n = 434)b
Mean  SD age (years) 427  131 472  129 < 0001 452  132
Sex
Male 125 (676) 184 (748) 0086 311 (717)
Female 60 (324) 62 (252) – 123 (283)
Race
Caucasian 184 (995) 241 (980) 0547 428 (986)
Mean  SD weight (kg) 767  150 840  177 < 0001 809  170
Mean  SD BMI (kg m2) 259  43 283  56 < 0001 273  53
Mean  SD waist circumference (cm) 926  138 993  153 < 0001 966  151
Mean  SD age at diagnosis of psoriasis (years) 237  129 303  142 0002 274  140
Number of patients with PsA 30 (162) 55 (224) 0499 86 (198)
Mean  SD time since first diagnosis of psoriasis (years) 196  125 175  113 0015 184  119
Mean  SD baseline PASI score 207  899c 215  999d 0777 212  96e
Baseline IGA mod 2011 score
0 (clear) 0 (0) 0 (0) – 0 (0)
1 (almost clear) 0 (0) 0 (0) – 0 (0)
2 (mild disease) 4 (22) 8 (33) – 12 (28)
3 (moderate disease) 103 (557) 132 (537) – 236 (544)
4 (severe disease) 77 (416) 106 (431) 0073 185 (426)
Missing 1 (05) 0 (0) – 1 (02)
Data are n (%) unless otherwise indicated. Cw6-NEG, HLA-Cw6 negative; Cw6-POS, HLA-Cw6-positive; BMI, body mass index; PsA, psoriatic
arthritis; IGA mod 2011, Investigator’s Global Assessment modified in 2011; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.
aP-values for categorical variables were calculated using the logistic model and for continuous variables were calculated using ANCOVA; bthree
patients with missing HLA-Cw6 assessment are included in the ‘Overall’ column. Cn = 184; dn = 246; en = 433.
© 2018 The Authors. British Journal of Dermatology
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to sex; 717% were males (Cw6-POS 676%; Cw6-NEG 748%;
P = 0086). Cw6-NEG patients had a significantly higher
mean  SD weight (8397  1774 vs. 7667  1504 kg;
P < 0001), body mass index (2833  562 vs.
2589  429 kg m2; P < 00001) and waist circumference
(9933  1526 vs. 9261  1377 cm; P = 0001) compared
with Cw6-POS patients. Mean  SD age at diagnosis of psoriasis
was significantly lower (P = 0002) in Cw6-POS patients
(237  129 years) compared with Cw6-NEG patients
(303  142 years). In total, 162% Cw6-POS and 224% Cw6-
NEG patients had concomitant PsA (P = 0499). Baseline
mean  SD PASI was comparable between the two cohorts
(Cw6-POS 207  899; Cw6-NEG 215  999; P = 0777).
Most patients had a baseline IGA mod 2011 score ≥ 3, in particu-
lar 544% with three and 426% with four, indicating moderate
or severe disease, respectively.
Efficacy
At week 16, PASI 90 (primary variable) was achieved in
804% (n = 148) of Cw6-POS and 797% (n = 196) of Cw6-
NEG patients [odds ratio (OR) 0753, 95% CI 044–128;
P = 0293] considering the nonresponder imputation
approach (Fig. 2a). The proportion of patients with a PASI 90
response at week 16 assessed using the LOCF approach was
equivalent to nonresponder imputation analysis. In particular,
considering the LOCF approach, the nonadjusted difference
between cohorts was 13 with a one-tailed 975% CI of
88, confirming that the proportion of Cw6-NEG patients
who achieved PASI 90 was not less than that observed in the
Cw6-POS cohort. In both cohorts, no differences were
observed in mean  SD absolute PASI at week 16 (Cw6-POS
136  358; Cw6-NEG 118  229) and week 24 (Cw6-
POS 115  334; Cw6-NEG 127  290 (Fig. 2b). The
repeated measure analysis of absolute change from baseline in
PASI total score over time showed that there was no signifi-
cant difference in the PASI changes between the two cohorts
at all time points (Fig. 3), in particular at week 16 the
(a)
(b)
Fig 2. (a) Proportion of HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-
negative (Cw6-NEG) patients achieving a 90% reduction in Psoriasis
Area and Severity Index (PASI 90) response at week 16 [nonresponder
imputation analysis, intent-to-treat (ITT) set]. (b) Absolute PASI scores
at baseline, and at weeks 16 and 24 in Cw6-POS and Cw6-NEG
patients (last observation carried forward approach, ITT set).
Fig 3. Percentage change from baseline Psoriasis Area and Severity Index (PASI) score over time (last observation carried forward approach,
intent-to-treat set). Cw6-NEG, HLA-Cw6 negative; Cw6-POS, HLA-Cw6-positive.
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least-sqaures mean of the difference (SE) was 008 (115)
(P = 0944) and 015 (117) at week 24 (P = 0898). Secuk-
inumab showed a rapid onset of action with a mean  SD
PASI score reduction from baseline of 756  211% and
732  223% at week 4 in the Cw6-POS and Cw6-NEG
cohorts, respectively.
Clinical response to secukinumab was assessed by measur-
ing the 50%/75%/90%/100% improvement from baseline in
(a) (b)
(c) (d)
(e)
Fig 4. The proportion of HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients achieving a (a) 50% improvement in Psoriasis
Area and Severity Index (PASI) from baseline (PASI 50); (b) 75% improvement in PASI (PASI 75); (c) 90% improvement in PASI (PASI 90); (d)
100% improvement in PASI (PASI 100); and (e) Investigator’s Global Assessment modified in 2011 (IGA mod 2011) 0/1 scores following
secukinumab treatment (nonresponder imputation analysis, intent-to-treat set). Error bars represent 95% confidence interval.
© 2018 The Authors. British Journal of Dermatology
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PASI (PASI 50, PASI 75, PASI 90 and PASI 100, respectively)
IGA mod 2011. The proportion of PASI 50/PASI 75/PASI 90/
PASI 100 responders was similar across the cohorts with
numerically comparable results throughout the 24 weeks of
treatment (Fig. 4). PASI 75 was achieved in 929% of Cw6-
POS and 927% of Cw6-NEG patients (OR 0706, 95% CI
031–162; P = 0412) at week 16, and these responses
remained stable until week 24. The largest difference between
the cohorts (639%, 95% CI 309 to 1565) was observed
for PASI 100 at 16 weeks (Cw6-POS 592%; Cw6-NEG
528%). At week 24, PASI 100 responses were numerically
similar in both cohorts (Cw6-POS 620%; Cw6-NEG 610%;
difference 098%, 95% CI 831 to 1012).
Differences between the cohorts in IGA mod 2011 0/1
responses varied from 198% to 403%. By week 16 > 80% of
patients achieved IGA mod 2011 0/1 scores in both cohorts
(Cw6-POS 848%; Cw6-NEG 854%; difference 058; 95% CI
764 to 610), and efficacy was maintained until week 24. The
mean  SD IGA mod 2011 scores were similar for both cohorts
at week 16 (Cw6-POS 05  084; Cw6-NEG 06  078) and
week 24 (Cw6-POS 05  082; Cw6-NEG 05  090).
Median time taken to achieve PASI 90 was 57 days for the
Cw6-POS cohort and 58 days for the Cw6-NEG cohort [hazard
ratio (HR) 1086, 95% CI 089–133; P = 0429). Median time
taken to achieve PASI 75 was 29 days for both Cw6-POS and
Cw6-NEG patients (HR 1025, 95% CI 084–125; P = 0807).
Safety
In total, 202 (465%) patients experienced at least one treat-
ment-emergent AE (TEAE). The overall summary of TEAEs is
shown in Table 2. The most commonly reported TEAEs in the
overall population (incidence ≥ 2%) were hypertension
(44%), pruritus (30%), headache (28%), arthralgia (25%),
influenza (23%) and increased blood creatine phosphokinase
(23%). Among the cohorts, 79 (427%) Cw6-POS patients
and 122 (496%) Cw6-NEG patients experienced TEAEs
(P = 0295). Serious TEAEs were reported in seven (38%)
and 14 (57%) patients in the Cw6-POS and Cw6-NEG
cohorts, respectively. One patient in the Cw6-NEG cohort died
of cardiac circulatory arrest during the study. Among the
TEAEs of special interest, two cases of neutropenia and one
case of Candida sp. infection were reported in the Cw6-NEG
cohort. No clinically relevant changes were observed in vital
signs and electrocardiographic findings.
Discussion
The results of this study demonstrate the efficacy of secuk-
inumab in patients with moderate-to-severe plaque-type psori-
asis, irrespective of HLA-Cw6 status. In this study population,
Cw6-POS patients were younger and had a significantly lower
age at diagnosis compared with Cw6-NEG patients, as previ-
ously reported.13,30–32 A high PASI 90 response was achieved
with secukinumab 300 mg irrespective of the HLA-Cw6 status,
with a fast reduction in absolute PASI. This is in contrast to
the results reported by other studies, wherein ustekinumab
has shown higher PASI 90 and 75 response rates in Cw6-POS
patients with moderate-to-severe psoriasis than Cw6-NEG
patients.17–19,33,34 In our study, PASI 75 was achieved in
> 90% in both cohorts by week 16. More than half of the
patients had complete skin clearance (PASI 100) by week 16
in both cohorts. These results are in agreement with the
CLEAR study, wherein up to 50% of patients treated with
secukinumab 300 mg achieved PASI 100 by weeks 12 and
20.22 The absolute PASI scores were reduced to a similar
extent in both Cw6-POS and Cw6-NEG patients throughout
the study period. These results show the consistent efficacy of
secukinumab in both cohorts. A retrospective study in 18
patients, stratified for HLA-Cw6 allele, treated with secuk-
inumab showed no significant difference in average PASI
improvement between the two groups (Cw6-POS 742%,
Cw6-NEG 624%; P = 0397). These results are in agreement
with our study with a larger cohort of patients.35
Consistent with the high PASI results, approximately 85% of
patients had achieved IGA 0/1 scores (clear/almost clear skin)
at week 16, and the scores were comparable across the two
cohorts. These results are clinically meaningful, as most of the
patients had moderate-to-severe disease at baseline, and show
that secukinumab provides a high level of skin clearance, irre-
spective of HLA-Cw6 status. Secukinumab showed a rapid onset
of action; by week 4 a PASI score reduction of almost 75% with
respect to baseline was observed in both cohorts. The median
Table 2 Summary of adverse events (safety set)
Cw6-POS
(n = 185)
Cw6-NEG
(n = 246)
Overall
(n = 434)a
Number of
patients with
TEAEs
79 (427) 122 (496) 202 (465)
Number of patients
with serious TEAEs
7 (38) 14 (57) 21 (48)
Number of patients
with TEAEs related
to the study drug
22 (119) 42 (171) 64 (147)
Number of patients
with TEAEs leading
to discontinuation of
the study drug
7 (38) 11 (45) 18 (41)
Deaths 0 (0) 1 (04) 1 (02)
TEAEs of special interest
Any TEAE 0 (0) 3 (12) 3 (07)
Neutropenia 0 (0) 2 (08) 2 (05)
Candida infection 0 (0) 1 (04) 1 (02)
Data are n (%). A patient with multiple adverse events (AEs) is
counted only once in the ‘Any TEAE’ row. A patient with multi-
ple AEs within a system organ class is counted only once for that
system organ class. A patient with multiple AEs with the same
preferred term is counted only once for that preferred term.
Cw6-NEG, HLA-Cw6 negative; Cw6-POS, HLA-Cw6 positive; TEAE,
treatment-emergent AE. aThree patients with missing Cw6 assess-
ment are included in the ‘Overall’ column.
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time to reach PASI 90 and PASI 75 was similar for both cohorts,
even if Cw6-POS patients had a shorter time of clearance during
the initial 8-week period, and there was minimal difference
beyond 2 months. These results are relevant as more than half
of the patients in this study were Cw6-NEG. The safety profile
of secukinumab was similar to that reported in previous stud-
ies.22,23,36,37 No statistically significant difference was detected
in the rate of TEAEs in both cohorts. No new or unexpected
safety signals were reported in the study.
In conclusion, secukinumab demonstrated efficacy and
safety in patients with moderate-to-severe plaque psoriasis.
Although Cw6-POS and Cw6-NEG patients have distinct clini-
cal features, the present study showed that secukinumab
achieved similar clinical responses in both cohorts after
24 weeks of treatment. Determination of HLA-Cw6 status for
secukinumab therapy is unnecessary, as it is highly effective
regardless of HLA-Cw6 status.
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